QuestionQ21
VerifiedIntroduction to Applying the ADMYou are acting as the Lead Architect for an Enterprise Architecture team within a leading multinational biotechnology company. The company operates in three major industries, including healthcare, crop production, and agriculture. Your team works in the healthcare division.
The healthcare division is developing a new vaccine and must demonstrate its effectiveness and safety in a set of clinical trials that meet the regulatory requirements of the relevant health authorities. These clinical trials are carried out by its research laboratories at multiple facilities worldwide. In addition to internal research and development activities, the healthcare division is also engaged in publicly funded collaborative research projects with industrial and academic partners.
The Enterprise Architecture team has been assigned an architecture project to build a secure system that will enable healthcare researchers to share information more easily about their clinical trials, and to work more collaboratively across the organization and with its partners. This system will also connect with external partners.
The Enterprise Architecture team uses the TOGAF ADM with extensions needed to support healthcare manufacturing practices and laboratory practices. Because the information being managed is highly sensitive, special care has been taken to ensure that each architecture domain addresses the relevant security and privacy issues.
The Vice President for Worldwide Clinical Research is the sponsor of the Enterprise Architecture activity. She has stated that disruptions must be minimized for the clinical trials, and that the rollout must be carried out incrementally.
You have been asked to recommend an approach for identifying the work packages for an incremental rollout that meets the requirements.
Based on the TOGAF standard, which of the following is the best answer?
Community Discussion